

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10563616	
	Filing Date		2006-08-09	
	First Named Inventor	George F. Vande Woude		
	Art Unit	1635		
	Examiner Name	Angell, Jon E		
	Attorney Docket Number	VAN067 P329		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10563616
Filing Date	2006-08-09
First Named Inventor	George F. Vande Woude
Art Unit	1635
Examiner Name	Angell, Jon E
Attorney Docket Number	VAN067 P329

1	BAUDINO, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., and Cleveland, J. L. (2002). c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16, 2530-2543.	<input type="checkbox"/>
2	BLEUEL, K., Popp, S., Fusenig, N. E., Stanbridge, E. J., and Boukamp, P. (1999). Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci U S A 96, 2065-2070.	<input type="checkbox"/>
3	BUSSOLINO, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119, 629-641.	<input type="checkbox"/>
4	CAO, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L. M., and Vande Woude, G. F. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 98, 7443-7448.	<input type="checkbox"/>
5	DAMERON, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.	<input type="checkbox"/>
6	DONG, G., Chen, Z., Li, Z. Y., Yeh, N. T., Bancroft, C. C., and Van Waes, C. (2001). Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61, 5911-5918.	<input type="checkbox"/>
7	DUESBERY, N. S., Resau, J., Webb, C. P., Koochekpour, S., Koo, H. M., Leppla, S. H., and Vande Woude, G. F. (2001). Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 98, 4089-4094.	<input type="checkbox"/>
8	DUESBERY, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D., and Vande Woude, G. F. (1998). Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734-737.	<input type="checkbox"/>
9	FERRARA, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29, 10-14.	<input type="checkbox"/>
10	FERRARA, N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2, 795-803.	<input type="checkbox"/>
11	FURGE, K. A., Zhang, Y. W., and Vande Woude, G. F. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19, 5582-5589.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10563616
Filing Date	2006-08-09
First Named Inventor	George F. Vande Woude
Art Unit	1635
Examiner Name	Angell, Jon E
Attorney Docket Number	VAN067 P329

12	GRANT, D. S., Kleinman, H. K., Goldberg, I. D., Bhargava, M. M., Nickoloff, B. J., Kinsella, J. L., Polverini, P., and Rosen, E. M. (1993). Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 90, 1937-1941.	<input type="checkbox"/>
13	HANAHAN, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.	<input type="checkbox"/>
14	HANAHAN, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.	<input type="checkbox"/>
15	JEFFERS, M., Rong, S., and Vande Woude, G. F. (1996). Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16, 1115-1125.	<input type="checkbox"/>
16	JIMENEZ, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6, 41-48.	<input type="checkbox"/>
17	KERBEL, R., and Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 727-739.	<input type="checkbox"/>
18	KUBA, K., Matsumoto, K., Date, K., Shimura, H., Tanaka, M., and Nakamura, T. (2000). HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60, 6737-6743.	<input type="checkbox"/>
19	LEWIS, T. S., Shapiro, P. S., and Ahn, N. G. (1998). Signal transduction through MAP kinase cascades. Adv Cancer Res 74, 49-139.	<input type="checkbox"/>
20	MORIYAMA, T., Kataoka, H., Hamasuna, R., Yokogami, K., Uehara, H., Kawano, H., Goya, T., Tsubouchi, H., Koono, M., and Wakisaka, S. (1998). Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 249, 73-77.	<input type="checkbox"/>
21	NIU, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008.	<input type="checkbox"/>
22	RAK, J., Mitsushashi, Y., Sheehan, C., Tamir, A., Vitoria-Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., and Kerbel, R. S. (2000). Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60, 490-498.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10563616
Filing Date	2006-08-09
First Named Inventor	George F. Vande Woude
Art Unit	1635
Examiner Name	Angell, Jon E
Attorney Docket Number	VAN067 P329

23	ROSEN, E. M., and Goldberg, I. D. (1995). Scatter factor and angiogenesis. Adv Cancer Res 67, 257-279.	<input type="checkbox"/>
24	SARGIANNIDOU, I., Zhou, J., and Tuszynski, G. P. (2001). The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 226, 726-733.	<input type="checkbox"/>
25	TRUSOLINO, L., and Comoglio, P. M. (2002). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2, 289-300.	<input type="checkbox"/>
26	VANDE WOUDE, G. F., Jeffers, M., Cortner, J., Alvord, G., Tsarfaty, I., and Resau, J. (1997). Met-HGF-SF: tumorigenesis, invasion and metastasis. In CIBA Foundation Symposium: Plasminogen-related growth factors, (John Wiley & Sons Ltd., Chichester), pp. 119-132.	<input type="checkbox"/>
27	ZHANG, Y. W., Wang, L. M., Jove, R., and Vande Woude, G. F. (2002). Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217-226.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.